Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
The NAACP has entered the VC space with a new fund that will invest in startups and fund managers that are focused on closing gaps facing communities of color.
Can a layoff lead to your next big thing? Issie Lapowsky, contributor for Inc. Magazine and Alphonzo Terrell, co-founder and CEO of Spill join us to discuss.
Meet Scorpion, the latest, Nvidia-powered service robot from Richtech Robotics which crafts personalized cocktails and wine selections based on your mood
Gina Heeb, finance reporter at The Wall Street Journal, joins us to discuss the current state of the real estate market and when things may turn around. Watch!
Managing Editor at Tom's Guide, Kate Kozuch, joins Cheddar to explain how Apple's AirPods now work as hearing aids and what she thinks of Apple Intelligence.
